RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
BioNexus Gene Lab Stock

BioNexus Gene Lab Equity 2025

BioNexus Gene Lab Equity

8.32 M USD

Ticker

BGLC

ISIN

US0906283066

In 2025, BioNexus Gene Lab's equity was 8.32 M USD, a -13.82% increase from the 9.66 M USD equity in the previous year.

BioNexus Gene Lab Aktienanalyse

What does BioNexus Gene Lab do?

BioNexus Gene Lab ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing BioNexus Gene Lab's Equity

BioNexus Gene Lab's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding BioNexus Gene Lab's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating BioNexus Gene Lab's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

BioNexus Gene Lab's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in BioNexus Gene Lab’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about BioNexus Gene Lab stock

What is the equity of BioNexus Gene Lab this year?

BioNexus Gene Lab has equity of 8.32 M USD this year.

What was the equity of BioNexus Gene Lab compared to the previous year?

The equity of BioNexus Gene Lab has increased/decreased by -13.82% decreased compared to the previous year.

What impact does a high equity have on investors of BioNexus Gene Lab?

A high equity is advantageous for investors of BioNexus Gene Lab as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of BioNexus Gene Lab?

A low equity can be a risk for investors of BioNexus Gene Lab, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of BioNexus Gene Lab affect the company?

An increase in equity of BioNexus Gene Lab can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of BioNexus Gene Lab affect the company?

A reduction in equity of BioNexus Gene Lab can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of BioNexus Gene Lab?

Some factors that can affect the equity of BioNexus Gene Lab include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of BioNexus Gene Lab so important for investors?

The equity of BioNexus Gene Lab is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can BioNexus Gene Lab take to change the equity?

To change equity, BioNexus Gene Lab can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does BioNexus Gene Lab pay?

Over the past 12 months, BioNexus Gene Lab paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BioNexus Gene Lab is expected to pay a dividend of 0 USD.

What is the dividend yield of BioNexus Gene Lab?

The current dividend yield of BioNexus Gene Lab is .

When does BioNexus Gene Lab pay dividends?

BioNexus Gene Lab pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of BioNexus Gene Lab?

BioNexus Gene Lab paid dividends every year for the past 0 years.

What is the dividend of BioNexus Gene Lab?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is BioNexus Gene Lab located?

BioNexus Gene Lab is assigned to the '-' sector.

Wann musste ich die Aktien von BioNexus Gene Lab kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of BioNexus Gene Lab from 9/20/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/20/2025.

When did BioNexus Gene Lab pay the last dividend?

The last dividend was paid out on 9/20/2025.

What was the dividend of BioNexus Gene Lab in the year 2024?

In the year 2024, BioNexus Gene Lab distributed 0 USD as dividends.

In which currency does BioNexus Gene Lab pay out the dividend?

The dividends of BioNexus Gene Lab are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von BioNexus Gene Lab

Our stock analysis for BioNexus Gene Lab Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioNexus Gene Lab Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.